ArticleJournal of clinical microbiology2006
Candida guilliermondii fungemia in patients with hematologic malignancies.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Snakes as sentinel of zoonotic yeasts and bio-indicators of environmental quality.Scientific reports · 2024Article
- Diagnosis and Treatment Challenges ofCase reports in infectious diseases · 2024Article
- Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020.Medical mycology · 2023Article
- Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Advances in prophylaxis and treatment of invasive fungal infections: perspectives on hematologic diseases.Blood research · 2022Review
- The Flo Adhesin Family.Pathogens (Basel, Switzerland) · 2021Review
- Expect the unexpected: fungemia caused by uncommon Candida species in a Turkish University Hospital.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Microbial levels on street foods and food preparation surfaces in Mangaung Metropolitan Municipality.Health SA = SA Gesondheid · 2021Article
- Candidemia due toCurrent medical mycology · 2019Article
- The Genomes of FourG3 (Bethesda, Md.) · 2018Article
- Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthroughInfection and drug resistance · 2018Article
- Increasing Non-Albicans Candida in Hematological Patients with Fluconazole Prophylaxis: A Case Series.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.Antimicrobial agents and chemotherapy · 2017Article
- Identification and Antifungal Susceptibility Profile of Candida guilliermondii and Candida fermentati from a Multicenter Study in China.Journal of clinical microbiology · 2016Article
- Disruption of Protein Mannosylation AffectsFrontiers in microbiology · 2016Article
- Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA.Emerging infectious diseases · 2015Article
- Intravenous Catheter-Associated Candidemia due to Candida membranaefaciens: The First Iranian Case.The journal of Tehran Heart Center · 2015Article
- Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin.Journal of clinical microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microbiological, clinical, and epidemiological features of most non-Candida albicans Candida species are well known, but much less is known about species such as Candida guilliermondii, an uncommon pathogen causing a variety of deep-seated infections in immunocompromised hosts. To characterize C. guilliermondii fungemia in patients with hematological malignancies and its susceptibility to antifungal drugs, all cases of C. guilliermondii fungemia diagnosed in our department between 1983 and 2005 were retrospectively analyzed and the literature was reviewed. C. guilliermondii caused 29/243 (11.7%) candidemia episodes diagnosed during the study period. Central venous catheters were the documented sources of candidemia in 19/29 episodes (65.5%), and invasive tissue infections were documented in 2 (6.9%). In the remaining eight, the catheter was not removed and the source of the fungemia remained obscure. Seven episodes ended in death, but only one could be attributed to invasive C. guilliermondii infection. Molecular typing data reveal no evidence of common infection sources. Isolates displayed high rates of in vitro susceptibility to amphotericin B (100%), voriconazole (95%), and fluconazole (90%) and lower rates of in vitro susceptibility to flucytosine (86%), itraconazole (76%), and caspofungin (33%). Our literature review confirms that C. guilliermondii is a significantly more frequent cause of candidemia among cancer patients compared with the general hospital population. It accounted for <1% of the total number of Candida bloodstream isolates reported in the articles we reviewed, with higher rates in Europe (1.4%) and Asia (1.8%) compared with North America (0.3%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.